Clinical efficacy of ganciclovir combined with transfer factor oral solution for pediatric infectious mononucleosis

This study investigates the clinical efficacy of ganciclovir combined with transfer factor oral solution in the treatment of patients with infectious mononucleosis (IM) to provide a reference for clinical application. A total of 150 children with IM who received treatment in our hospital from 2020 to 2022 were randomly selected as the research subjects. They were randomly divided into a control group receiving intravenous administration of ganciclovir (n = 75) and an observation group receiving transfer factor oral liquid in combination with intravenous administration of ganciclovir (n=75). The results showed that after treatment, the serum levels of CK-MB, CK, CRP, IL-6, and TNF-α were significantly reduced in both groups. The observation group showed lower levels than the control group. Additionally, peripheral blood CD4+ T cells, CD4+/CD8+ ratio, and Tfr expression were higher in the observation group compared to the control group, while the level of CD8+ T cells was lower than that of the control group. Furthermore, there were no significant changes in the levels of IgA, IgM, and IgG antibodies in the two groups before and after treatment. In conclusion, the combination therapy of transfer factor oral solution and ganciclovir demonstrates favorable clinical efficacy and safety in the treatment of children with IM, as it effectively reduces inflammatory reactions, regulates cellular immune function, promotes Tfr differentiation, and shortens recovery time.